Interchange Capital Partners LLC Sells 896 Shares of Eli Lilly and Company $LLY

Key Points

• Interchange Capital Partners LLC reduced its stake in Eli Lilly and Company by 71.1%, selling 896 shares and holding 364 shares valued at $284,000.
• Institutional investors now own 82.53% of Eli Lilly's stock, with PNC Financial Services increasing its holdings by 97.5% during the 1st quarter.
• Eli Lilly reported a 37.6% revenue increase year over year, reaching $15.56 billion in its latest quarterly earnings, and set its FY 2025 EPS guidance between $21.750-23.000.

Interchange Capital Partners LLC lessened its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 71.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 364 shares of the company's stock after selling 896 shares during the period. Interchange Capital Partners LLC's holdings in Eli Lilly and Company were worth $284,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. PNC Financial Services Group Inc. increased its holdings in Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock worth $83,669,349,000 after purchasing an additional 50,002,551 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Eli Lilly and Company by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock worth $65,432,218,000 after buying an additional 4,975,395 shares during the period. Wellington Management Group LLP grew its position in shares of Eli Lilly and Company by 0.6% during the 1st quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company's stock worth $10,495,261,000 after buying an additional 81,587 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Eli Lilly and Company by 13.3% during the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company's stock valued at $4,808,443,000 after buying an additional 682,203 shares during the period. Finally, Nuveen LLC bought a new stake in shares of Eli Lilly and Company in the first quarter valued at about $4,613,912,000. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

Shares of LLY opened at $812.65 on Wednesday. The company has a 50 day moving average of $744.36 and a two-hundred day moving average of $765.86. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63. The company has a market cap of $769.14 billion, a price-to-earnings ratio of 53.11, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Daniel Skovronsky acquired 1,000 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gabrielle Sulzberger bought 117 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock valued at $2,894,841 in the last 90 days. 0.14% of the stock is owned by insiders.

Analysts Set New Price Targets

LLY has been the subject of a number of research reports. Daiwa America lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Guggenheim boosted their price objective on shares of Eli Lilly and Company from $875.00 to $948.00 and gave the stock a "buy" rating in a research note on Wednesday, October 8th. Finally, JPMorgan Chase & Co. dropped their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research report on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus target price of $948.06.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.